Meta-analysis finds shared endocannabinoid gene changes across myopathies

Endocannabinoid system remodeling in human myopathies: a meta-analysis of skeletal muscle transcriptomes.

Journal of muscle research and cell motility โ€ข โ€ข Meta-Analysis โ€ข Highly Relevant
๐Ÿค–

AI Summary

This retrospective meta-analysis asked whether the endocannabinoid system is altered in human muscle diseases. Researchers reanalyzed public muscle RNA-sequencing datasets, comparing biopsies from people with several types of myopathy with samples from controls. The main finding was a consistent pattern across disease subtypes: CNR1, which encodes the CB1 receptor, was upregulated, while FAAH, an enzyme that breaks down anandamide and related molecules, was downregulated. The abstract reports 328 patient biopsies and 173 control samples.

The results suggest that altered endocannabinoid signaling may be a shared feature of muscle degeneration, while enzymes involved in 2-AG metabolism varied by disease. This is a meta-analysis of gene-expression data, not a trial of cannabis or cannabinoid treatment. It cannot show whether these expression changes cause myopathy, affect symptoms, or indicate a useful treatment target; the authors call for studies linking endocannabinoid changes over time with clinical measures. This is an abstract-based summary, not a review of the full text.

๐Ÿ’ก Key Findings

1
Across the myopathy datasets, CNR1 expression was upregulated compared with controls (log2FC = 0.43, q < 0.001).
High
90%
2
FAAH, which helps break down anandamide and related molecules, was consistently downregulated (log2FC = -0.56, q < 0.001).
High
90%
3
Enzymes involved in 2-AG metabolism showed disease-specific regulation, rather than one uniform pattern across myopathies.
High
80%
4
The analysis identifies gene-expression changes, but cannot establish that endocannabinoid remodeling causes muscle disease or that cannabinoid treatment would help.
High
95%

๐Ÿ“„ Original Abstract

Preclinical studies indicate that the endocannabinoid system plays an important role in skeletal muscle inflammation, regeneration and metabolism, yet its involvement in human myopathies remains undefined. This study systematically investigated whether endocannabinoid system remodeling occurs in muscle of patients with myopathies. A retrospective meta-analysis was performed using publicly available bulk RNA-sequencing datasets from the Gene Expression Omnibus. In total, 328 muscle biopsies from patients with limb-girdle muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, inflammatory myopathies, Duchenne/Becker muscular dystrophy, mitochondrial and collagen VI-related myopathy, and 173 control samples were included. Differential expression analyses were conducted per dataset using DESeq2, followed by random-effects meta-analyses for endocannabinoid targets and key endocannabinoid enzymes, with false discovery rate correction. Across disease subtypes, consistent remodeling of the endocannabinoid system was observed. Cannabinoid receptor 1 (CNR1) expression was overall upregulated (log2FCโ€‰=โ€‰0.43, qโ€‰<โ€‰0.001), while fatty acid amide hydrolase (FAAH), the primary enzyme responsible for anandamide and N-acylethanolamine degradation, was consistently downregulated (log2FC = -0.56, qโ€‰<โ€‰0.001). CNR1 exhibited the lowest heterogeneity of all genes analyzed. Enzymes involved in 2-arachidonoylglycerol metabolism displayed disease-specific regulation. Results were robust to sex adjustment and alternative models. This meta-analysis provides the first comprehensive evidence that endocannabinoid signaling is consistently remodeled in human myopathies, across myopathies of different etiology. The downregulation of FAAH and upregulation of CNR1 suggest altered endocannabinoid tone as a shared feature of muscle degeneration. These findings support integrative studies combining longitudinal endocannabinoid and clinical data to understand how endocannabinoid remodeling drives muscle plasticity.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.